By
Trending Posts
Is Sanofi’s $632M AI Bet on Formation Bio…
French pharma giant doubles down on AI-native R&D with gusacitinib licensing deal targeting new inflammatory indication Key Takeaways…
Can USC’s AI Implant Replace Opioids in Chronic…
USC and UCLA unveil AI-powered, wireless spinal implant that delivers real-time, adaptive pain relief without drugs, batteries, or…
Can Tampa General’s New AI Ambient Tech Redefine…
AI-powered voice technology by Microsoft brings ambient documentation to frontline nurses, boosting care quality and clinical efficiency Key…
Can Ottai’s New AI Biosensor Reshape Chronic Disease…
AI-powered wearable from Oxford-founded Ottai offers real-time insights, personalized support, and voice-driven healthcare experience Key Takeaways AI-Driven Transformation…
Accelerating Drug Discovery with Artificial Intelligence: Strategic Insights…
Executive SummaryThe convergence of artificial intelligence (AI) and drug discovery is a strategic imperative. Pharmaceutical giants including Sanofi,…
Is Merck’s WINREVAIR Set to Redefine First-Year PAH…
Key Takeaways:• Game-Changing Efficacy: WINREVAIR™ (sotatercept-csrk) cut clinical worsening risk in PAH by a statistically significant margin in…
Can Sanofi’s Sarclisa-VRd Regimen, Backed by EMA’s CHMP,…
Key Highlights EMA’s CHMP Endorses Sarclisa-VRd for Frontline Multiple Myeloma in Transplant-Eligible AdultsOn June 23, 2025, Sanofi announced…
Could Lilly’s Oral GLP-1 Orforglipron Revolutionize Type 2…
Key Highlights Orforglipron Delivers Clinically Meaningful Glycemic and Weight ImprovementsThe ACHIEVE-1 Phase 3 trial established orforglipron’s efficacy, showing…
How Caris Life Sciences’ $7.6B IPO the Breakout…
Key Highlights AI Meets Molecular Medicine: A New TechBio Contender EmergesCaris Life Sciences’ successful IPO positions it as…
Trending Posts
Latest Stories
Will AI-Powered Querent™ by Mango Sciences Transform Veeda Lifesciences’ Global Clinical Trial Efficiency?
Key Highlights AI-Driven Precision in Global Trial RecruitmentVeeda Lifesciences, a global CRO, has announced a…
Can Revolution Medicines and Iambic’s AI Alliance Accelerate the Discovery of Next-Gen Cancer Drugs Targeting RAS Mutations?
Key Highlights AI-Powered Discovery for RAS-Addicted CancersRevolution Medicines, a leader in targeting RAS-driven cancers, is…
Can Johnson & Johnson’s 6-Point AI Strategy Revolutionize Surgery, Drug Discovery, and Global Patient Care?
Key Highlights From Experimentation to Execution: Focused AI for Measurable OutcomesAfter piloting 900+ generative AI…
At VivaTech 2025, Can NVIDIA, Sanofi, and TetraScience Unlock the Full Potential of Scientific AI Despite a 20-Exabyte Data Barrier?
Key Highlights The 20-Exabyte Problem: Data, Not Models, Is the Limiting FactorAt The Rise of…
Gallery
